1
|
Vanacker H, Brahmi M, Cassier P, Pissaloux D, Boyault S, Tirode F, Blay JY, Dufresne A. 66P Therapeutic opportunities in sarcomas and rare tumors: What path for antibody-drug conjugates? ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
2
|
Vanacker H, Attignon V, Brahmi M, Dufresne A, Cassier P, Carbonnaux M, Pissaloux D, Boyault S, Wang Q, Tredan O, Tirode F, Blay JY. 6MO Pan-cancer characterization of receptor tyrosine kinases alterations to sort targetable drivers from passengers. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Mangiante L, Alcala N, Di Genova A, Sexton-Oates A, Le Stang N, Boyault S, Cuenin C, Damiola F, Voegele C, MESOBANK M, Jean D, Lantuejoul S, Ghantous A, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov L, Salle FG, Foll M, Fernandez-Cuesta L. OA04.05 MESOMICS Project: Using Whole-Genome Sequencing Data to Fill the Gaps in Malignant Pleural Mesothelioma Molecular Studies. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Mangiante L, Alcala N, Di Genova A, Sexton-Oates A, Giacobi C, Le-Stang N, Boyault S, Damiola F, Mesobank M, Lantuejoul S, Caux C, Girard N, Galateau Salle F, Foll M, Fernandez-Cuesta L. OA09.03 MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Alcala N, Mangiante L, Le Stang N, Gustafson C, Boyault S, Damiola F, Alcala K, Mazieres J, Blay J, Lantuejoul S, Bueno R, Caux C, Girard N, Mckay J, Foll M, Sallé FG, Fernandez-Cuesta L. MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Alcala N, Mangiante L, Poret A, Gabriel A, Derks J, Moonen L, Boyault S, Le Stang N, Ghantous A, Tabone-Eglinger S, Damiola F, Blay J, Mckay J, Dingemans A, Speel E, Caux C, Girard N, Lantuejoul S, Dayton T, Sallé FG, Fernandez-Cuesta L, Foll M. OA08.02 A Multidisciplinary Multi-Omics Study of Spatial and Temporal Tumor Evolution in Thoracic Cancers with Clinical Implications. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derks J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmuller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojsic J, Deleuze JF, Herceg Z, Viari A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 2019; 10:3407. [PMID: 31431620 PMCID: PMC6702229 DOI: 10.1038/s41467-019-11276-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 07/02/2019] [Indexed: 02/06/2023] Open
Abstract
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value of OTP expression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.
Collapse
Affiliation(s)
- N Alcala
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - N Leblay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A A G Gabriel
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Mangiante
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - D Hervas
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - T Giffon
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A S Sertier
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - A Ferrari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - J Derks
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - A Ghantous
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - T M Delhomme
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Chabrier
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Cuenin
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - B Abedi-Ardekani
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Boland
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - R Olaso
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - V Meyer
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - J Altmuller
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
| | - F Le Calvez-Kelm
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - G Durand
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - C Voegele
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - S Boyault
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
| | - L Moonen
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Lemaitre
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - P Lorimier
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - A C Toffart
- Pulmonology-Physiology Unit, Grenoble Alpes University Hospital, 38700, La Tronche, France
| | - A Soltermann
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
| | - J H Clement
- Department Hematology and Medical Oncology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany
| | - J Saenger
- Bad Berka Institute of Pathology, Robert-Koch-Allee 9, 99438, Bad Berka, Germany
| | - J K Field
- Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 6 West Derby Street, L7 8TX, Liverpool, UK
| | - M Brevet
- Pathology Institute, Hospices Civils de Lyon, University Claude Bernard Lyon 1, 59 Boulevard Pinel, 69677, BRON Cedex, France
| | - C Blanc-Fournier
- CLCC François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France
| | - F Galateau-Salle
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - N Le Stang
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - P A Russell
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Wright
- St. Vincent's Hospital and University of Melbourne, Victoria Parade, Fitzroy, Melbourne, VIC, 3065, Australia
| | - G Sozzi
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - U Pastorino
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - S Lacomme
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - J M Vignaud
- Nancy Regional University Hospital, CHRU, CRB BB-0033-00035, INSERM U1256, 29 Avenue du Maréchal de Lattre de Tassigny, 54035, Nancy Cedex, France
| | - V Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice Hospital, Biobank BB-0033-00025, IRCAN Inserm U1081 CNRS 7284, University Côte d'Azur, 30 avenue de la voie Romaine, CS, 51069-06001, Nice Cedex 1, France
| | - O T Brustugun
- Drammen Hospital, Vestre Viken Health Trust, Vestre Viken HF, Postboks 800, 3004, Drammen, Norway
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | - M Lund-Iversen
- Institute of Cancer Research, Oslo University Hospital, Ullernchausseen 70, 0379, Oslo, Norway
| | | | - L A Muscarella
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - P Graziano
- Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, 71013, San Giovanni Rotondo FG, Italy
| | - H Popper
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - J Stojsic
- Department of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Pasterova 2, Belgrade, 11000, Serbia
| | - J F Deleuze
- Centre National de Recherche en Génomique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, 2 rue Gaston Crémieux, CP 5706, 91057, Evry Cedex, France
| | - Z Herceg
- International Agency for Research on Cancer (IARC/WHO), Section of Mechanisms of Carcinogenesis, 150 Cours Albert Thomas, 69008, Lyon, France
| | - A Viari
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - P Nuernberg
- Cologne Centre for Genomics (CCG) and Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Weyertal 115, 50931, Cologne, Germany
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Straße 26, 50931, Cologne, Germany
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, and Inter-Hospital Pathology Division, IRCCS Multimedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy
| | - A M C Dingemans
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - M Milione
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Roz
- Pathology Division Fondazione, IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010, Graz, Austria
| | - M Volante
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - M G Papotti
- Department of Oncology, University of Turin, Pathology Division, Via Santena 7, 10126, Torino, Italy
| | - C Caux
- Department of Immunity, Virus, and Inflammation, Cancer Research Centre of Lyon (CRCL), 28 Rue Laennec, 69008, Lyon, France
| | - J Sandoval
- Health Research Institute La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, 46026, Valencia, Spain
| | - H Hernandez-Vargas
- Cancer Research Centre of Lyon (CRCL), Inserm U 1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, 28 Rue Laennec, 69008, Lyon, France
| | - E Brambilla
- Institute for Advanced Biosciences, Site Santé, Allée des Alpes, 38700, La Tronche, Grenoble, France
| | - E J M Speel
- Maastricht University Medical Centre (MUMC), GROW School for Oncology and Developmental Biology, P.O. Box 5800, 6202, AZ, Maastricht, The Netherlands
| | - N Girard
- Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
- European Reference Network (ERN-EURACAN), 28 rue Laennec, 69008, Lyon, France
| | - S Lantuejoul
- Synergie Lyon Cancer, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
- Translational Research and Innovation Department, Cancer Genomic Platform, 28 Rue Laennec, 69008, Lyon, France
- Department of Pathology, Centre Léon Bérard, 28, rue Laennec, 69373, Lyon Cedex 8, France
| | - J D McKay
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - M Foll
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France
| | - L Fernandez-Cuesta
- International Agency for Research on Cancer (IARC/WHO), Section of Genetics, 150 Cours Albert Thomas, 69008, Lyon, France.
| |
Collapse
|
8
|
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol 2019; 30:757-765. [PMID: 30865223 DOI: 10.1093/annonc/mdz080] [Citation(s) in RCA: 105] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
Abstract
BACKGROUND Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological subtypes. We aim to explore the feasibility, efficacy and therapeutic impact of molecular profiling in routine setting. PATIENTS AND METHODS This multicentric prospective study enrolled adult or pediatric patients with solid or hematological advanced cancer previously treated in advanced/metastatic setting and noneligible to curative treatment. Each molecular profile was established on tumor, relapse or biopsies, and reviewed by a molecular tumor board (MTB) to identify molecular-based recommended therapies (MBRT). The main outcome was to assess the incidence rate of genomic mutations in routine setting, across specific histological types. Secondary objectives included a description of patients with actionable alterations and for whom MBRT was initiated, and overall response rate. RESULTS Four centers included 2579 patients from February 2013 to February 2017, and the MTB reviewed the molecular profiles achieved for 1980 (76.8%) patients. The most frequently altered genes were CDKN2A (N = 181, 7%), KRAS (N = 177, 7%), PIK3CA (N = 185, 7%), and CCND1 (N = 104, 4%). An MBRT was recommended for 699/2579 patients (27%), and only 163/2579 patients (6%) received at least one MBRT. Out of the 182 lines of MBRT initiated, 23 (13%) partial responses were observed. However, only 0.9% of the whole cohort experienced an objective response. CONCLUSION An MBRT was provided for 27% of patients in our study, but only 6% of patients actually received matched therapy with an overall response rate of 0.9%. Molecular screening should not be used at present to guide decision-making in routine clinical practice outside of clinical trials.This trial is registered with ClinicalTrials.gov, number NCT01774409.
Collapse
Affiliation(s)
- O Trédan
- Departments of Medical Oncology, University Claude Bernard
| | - Q Wang
- Translational Research and Innovation
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - B You
- Department of Medical Oncology, Lyon Sud Hospital Center, CITOHL, Institute of Cancerology, Hospices Civils de Lyon (IC-HCL), Lyon; Faculty of Medicine-Lyon Sud, EMR UCBL/HCL 3738, University of Lyon 1, Oullins
| | - N Bonnin
- Department of Medical Oncology, Lyon Sud Hospital Center, CITOHL, Institute of Cancerology, Hospices Civils de Lyon (IC-HCL), Lyon
| | - O Collard
- Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez
| | - C Leyronnas
- Department of Medical Oncology, Mutualist Hospital Group, Grenoble
| | | | - C Baudet
- Synergie Lyon Cancer, Bio-Informatics Platform
| | - E Sohier
- Synergie Lyon Cancer, Bio-Informatics Platform
| | | | - A Viari
- Synergie Lyon Cancer, Bio-Informatics Platform
| | - S Boyault
- Translational Research and Innovation
| | | | | | | | - C Rodriguez
- BioPathology, Léon Bérard Cancer center, Lyon
| | - V Agrapart
- Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France
| | - V Corset
- Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France
| | - G Garin
- Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France
| | - S Chabaud
- Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France
| | - D Pérol
- Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France
| | - J-Y Blay
- Departments of Medical Oncology, University Claude Bernard.
| |
Collapse
|
9
|
Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, Irani J, Leroy X, Villers A, Fournier G, Doucet L, Boyault S, Brureau L, Multigner L, Diedhiou A, Roupret M, Compérat E, Blanchet P, de Reyniès A, Cussenot O. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol 2018; 29:1814-1821. [DOI: 10.1093/annonc/mdy224] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
10
|
Huet S, Tesson B, Jais J, Feldman A, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Xerri L, Ansell S, Tarte K, Boyault S, Haioun C, Link B, Feugier P, Lopez-Guillermo A, Brice P, Hayette S, Jardin F, Offner F, Gentien D, Viari A, Campo E, Cerhan J, Salles G. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Huet
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Tesson
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - J. Jais
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - A.L. Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - L. Magnano
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - E. Thomas
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - A. Traverse-Glehen
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Albaud
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - L. Xerri
- Department of Bio-Pathology, Institut Paoli-Calmettes; Aix-Marseille University; Marseille; France
| | - S. Ansell
- Hematology; Mayo Clinic; Rochester USA
| | - K. Tarte
- INSERM U917; Université Rennes 1, EFS Bretagne, CHU Rennes; Rennes France
| | - S. Boyault
- Département de Recherche Translationnelle et d'Innovation, Génomique des Cancers, Centre Léon Bérard; Lyon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; Assistance Publique-Hopitaux de Paris; Créteil France
| | - B. Link
- Department of Medicine; University of Iowa; Iowa City USA
| | - P. Feugier
- Hematology; Nancy University Hospital; Vandoeuvre-Lès-Nancy France
| | - A. Lopez-Guillermo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - P. Brice
- Hématologie; Assistance Publique-Hopitaux de Paris; Paris France
| | - S. Hayette
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - F. Jardin
- Inserm U1245, Henri Becquerel Comprehensive Cancer Center; Rouen France
| | - F. Offner
- Hematology; Universitat Ziekenhuis Gent; Ghent Belgium
| | - D. Gentien
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - A. Viari
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - E. Campo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - J.R. Cerhan
- Department of Health Sciences Research; Mayo Clinic; Rochester USA
| | - G. Salles
- Service d'hématologie Marcel Bérard; CHLS, Hospices Civils de Lyon; Pierre-Bénite France
| |
Collapse
|
11
|
Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier AS, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment.
Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098).
Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification.
Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants.
Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Collapse
Affiliation(s)
- A Vincent-Salomon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Ferrari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - X Pivot
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Macgrogan
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Arnould
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Treilleux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Romieux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A-S Sertier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - E Thomas
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Tonon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - S Boyault
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - J Kielbassa
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - V Letexier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Pauporte
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Birbaum
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - P Saintigny
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Cox
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Viari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| |
Collapse
|
12
|
Boyault S, Drouet Y, Lasset C, Navarro C, Puisieux A, Bachelot TD, Wang Q. Frequent and subtype-related genetic mutational signature suggesting the involvement of specific signaling pathway. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C, Cunha AS, Bioulac-Sage P, Perret C. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2006; 26:774-80. [PMID: 16964294 DOI: 10.1038/sj.onc.1209824] [Citation(s) in RCA: 178] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of beta-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.
Collapse
Affiliation(s)
- J Zucman-Rossi
- INSERM U674 IFR105, Paris Saint-Louis, CEPH, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, Bécuwe P, Dauça M, Netter P, Terlain B, Bordji K. 15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. FEBS Lett 2001; 501:24-30. [PMID: 11457450 DOI: 10.1016/s0014-5793(01)02614-x] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The activation of peroxisome proliferator-activated receptor gamma (PPARgamma) has been shown to inhibit the production and the effects of proinflammatory cytokines. Since interleukin-1beta (IL-1beta) directly mediates cartilage degradation in osteoarthritis, we investigated the capability of PPARgamma ligands to modulate IL-1beta effects on human chondrocytes. RT-PCR and Western blot analysis revealed that PPARgamma expression was decreased by IL-1beta. 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), in contrast to troglitazone, was highly potent to counteract IL-1beta-induced cyclooxygenase-2 and inductible nitric oxide synthase expression, NO production and the decrease in proteoglycan synthesis. Western blot and gel-shift analyses demonstrated that 15d-PGJ2 inhibited NF-kappaB activation, while troglitazone was ineffective. Although 15d-PGJ2 attenuated activator protein-1 binding on the DNA, it potentiated c-jun migration in the nucleus. The absence or the low effect of troglitazone suggests that 15d-PGJ2 action in human chondrocytes is mainly PPARgamma-independent.
Collapse
Affiliation(s)
- S Boyault
- Laboratoire de Pharmacologie, UMR 7561 CNRS-Université Henri Poincaré Nancy I, Faculté de Médecine, Vandoeuvre-lès-Nancy, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|